Growth hormone for "antiaging" [8]

JAMA

Volumn 295, Issue 8, 2006, Pages 889-

  Dalle, Claude ^a   Claude, Vicario ^b  

^a Autonomous University of Barcelona ^*

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH HORMONE; HUMAN GROWTH HORMONE;

BRAIN TUMOR; CANCER; CANCER INCIDENCE; CANCER MORTALITY; COHORT ANALYSIS; GASTROINTESTINAL TUMOR; GROWTH HORMONE DEFICIENCY; HORMONE SUBSTITUTION; HUMAN; LETTER; PRIORITY JOURNAL; SURVIVAL TIME; TUMOR RECURRENCE; AGING; DRUG EFFECT; NOTE;

AGING; HUMAN GROWTH HORMONE; HUMANS;

EID: 33644538639     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.295.8.889-a     Document Type: Letter

References (5)

1. Perls TT, Reisman NR, Olshansky SJ. Provision or distribution of growth hormone for "antiaging": clinical and legal issues. JAMA. 2005;294:2086-2090.
2. Wuster C, Melchinger U, Eversmann T, et al. Reduced incidence of sideeffects of growth hormone substitution in 404 patients with hypophyseal insufficiency: results of a multicenter indications study. Med Klin (Munich). 1998;93:585-591.
3. Swerdlow AJ, Reddingius RE, Higgins CD, et al. Growth hormone treatment of children with brain tumors and risk of tumor recurrence. J Clin Endocrinol Metab. 2000;85:4444-4449.
4. Tacke J, Bolder U, Herrmann A, Berger G, Jauch KW. Long-term risk of gastrointestinal tumor recurrence after postoperative treatment with recombinant human growth hormone. JPEN J Parenter Enteral Nutr. 2000;24:140-144.
5. Svensson J, Bengtsson BA, Rosen T, et al. Malignant disease and cardiovascular morbidity in hypopituitary adults with or without growth hormone replacement therapy. J Clin Endocrinol Metab. 2004;89:3306-3312.